Related Experiment Video
Updated: May 5, 2026

A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation
Published on: April 27, 2019
Predictive scoring systems for mortality in heart transplant patients with liver cirrhosis
Hyo-Hyun Kim1, Young-Nam Youn2
1Department of Thoracic & Cardiovascular Surgery, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.
Insights
The Model for End-Stage Liver Disease (MELD) and MELD-XI scores effectively predict mortality risk in cirrhosis patients undergoing heart transplantation. These scores, along with Child-Turcotte-Pugh (CTP), aid in risk stratification for improved patient outcomes.
Area of Science:
- Cardiology
- Hepatology
- Transplantation Medicine
Background:
- Patients with advanced heart failure and liver cirrhosis face high mortality and morbidity post-heart transplantation.
- Accurate risk stratification is crucial for managing these complex patients.
Purpose of the Study:
- To compare the predictive performance of Model for End-Stage Liver Disease (MELD), MELD-XI, and Child-Turcotte-Pugh (CTP) scores.
- To evaluate their utility in risk prediction for patients with cirrhosis undergoing heart transplantation.
Main Methods:
- Retrospective analysis of 66 consecutive patients undergoing heart transplantation with liver cirrhosis (1994-2022).
- Calculation of preoperative MELD, MELD-XI, and CTP scores.
- Cox regression and ROC curve analysis to assess predictive accuracy for all-cause mortality.
Main Results:
- MELD and MELD-XI scores were significantly different between survivors and non-survivors (p<0.01).
- MELD, MELD-XI, and CTP scores were independently associated with all-cause mortality (HRs ranging from 1.07 to 1.43).
- Optimal MELD, MELD-XI, and CTP cut-offs were 12.2, 12.0, and 7.5, respectively, with AUCs of 0.75, 0.69, and 0.73.
Conclusions:
- MELD and MELD-XI scores demonstrate significant predictive value for mortality in this patient cohort.
- These established scoring systems can serve as valuable tools for risk stratification in liver cirrhosis patients undergoing heart transplantation.
Abstract:
To compare the Model for End-Stage Liver Disease (MELD), MELD-XI, and Child-Turcotte-Pugh (CTP) scores for risk prediction in patients with cirrhosis undergoing heart transplantation. This study enrolled 66 consecutive patients (26 males; median age, 46 [18-68] years) with liver cirrhosis who underwent heart transplantation at our institution from 1994 to 2022. Potential preoperative outcome predictors and the preoperative MELD, MELD-XI, and CTP scores were calculated. The median follow-up duration was 45.2 months. The MELD (p = 0.01) and MELD-XI scores (p < 0.01) were significantly different between survivors and non-survivors. Cox regression analysis showed that high MELD (hazard ratio [HR] 1.07; 95% confidence interval [CI], 1.03-1.11; p < 0.01), MELD-XI (HR, 1.16; 95% CI, 1.06-1.21; p < 0.01), and CTP scores (HR, 1.43; 95% CI, 1.20-1.75; p = 0.01) were associated with the risk of all-cause mortality. Receiver operating characteristic curve analysis revealed that the optimal cut-off values of MELD, MELD-XI, and CTP scores were 12.2, 12.0, and 7.5, respectively (sensitivity: 69.2, 61.5, and 69.2%; specificity: 68.6, 60.0, and 62.9%, respectively) for all-cause mortality (area under the curve: 0.75, 0.69, and 0.73, respectively). Patients with advanced heart failure and liver cirrhosis have high mortality and morbidity rates after heart transplantation. However, these scoring systems can be used as risk stratification tools in patients with liver cirrhosis undergoing heart transplantation.Research registration unique identifying number: Research Registry (UIN: resarchregistry10791).
More Related Videos
11:26Heterotopic Auxiliary Whole Liver Rat Transplant Model Utilizing a Hepaticoureterostomy for Allograft Rejection Studies
Published on: March 8, 2024
08:49Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems
Published on: August 2, 2024
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Kidney Transplant I: Introduction